123 related articles for article (PubMed ID: 2140925)
1. Alteration of retinol-binding-protein concentrations by the synthetic retinoid fenretinide in healthy human subjects.
Dimitrov NV; Meyer CJ; Perloff M; Ruppenthal MM; Phillipich MJ; Gilliland D; Malone W; Minn FL
Am J Clin Nutr; 1990 Jun; 51(6):1082-7. PubMed ID: 2140925
[TBL] [Abstract][Full Text] [Related]
2. Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients.
Formelli F; Carsana R; Costa A; Buranelli F; Campa T; Dossena G; Magni A; Pizzichetta M
Cancer Res; 1989 Nov; 49(21):6149-52. PubMed ID: 2529028
[TBL] [Abstract][Full Text] [Related]
3. Secretion of vitamin A and retinol-binding protein into plasma is depressed in rats by N-(4-hydroxyphenyl)retinamide (fenretinide).
Smith JE; Lawless DC; Green MH; Moon RC
J Nutr; 1992 Oct; 122(10):1999-2009. PubMed ID: 1388202
[TBL] [Abstract][Full Text] [Related]
4. In vitro interaction of fenretinide with plasma retinol-binding protein and its functional consequences.
Berni R; Formelli F
FEBS Lett; 1992 Aug; 308(1):43-5. PubMed ID: 1386578
[TBL] [Abstract][Full Text] [Related]
5. N-(4-hydroxyphenyl)retinamide (fenretinide) induces retinol-binding protein secretion from liver and accumulation in the kidneys in rats.
Schaffer EM; Ritter SJ; Smith JE
J Nutr; 1993 Sep; 123(9):1497-503. PubMed ID: 8360775
[TBL] [Abstract][Full Text] [Related]
6. Retinol-binding protein secretion from the liver of N-(4-hydroxyphenyl) retinamide-treated rats.
Ritter SJ; Smith JE
Biochim Biophys Acta; 1996 Jun; 1290(2):157-64. PubMed ID: 8645719
[TBL] [Abstract][Full Text] [Related]
7. Identification of the fenretinide metabolite 4-oxo-fenretinide present in human plasma and formed in human ovarian carcinoma cells through induction of cytochrome P450 26A1.
Villani MG; Appierto V; Cavadini E; Valsecchi M; Sonnino S; Curley RW; Formelli F
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6265-75. PubMed ID: 15448016
[TBL] [Abstract][Full Text] [Related]
8. Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide.
Sabichi AL; Modiano MR; Lee JJ; Peng YM; Xu MJ; Villar H; Dalton WS; Lippman SM
Clin Cancer Res; 2003 Jul; 9(7):2400-5. PubMed ID: 12855611
[TBL] [Abstract][Full Text] [Related]
9. Secretion of N-(4-hydroxyphenyl) retinamide-retinol-binding protein from liver parenchymal cells: evidence for reduced affinity of the complex for transthyretin.
Holven KB; Natarajan V; Gundersen TE; Moskaug JO; Norum KR; Blomhoff R
Int J Cancer; 1997 May; 71(4):654-9. PubMed ID: 9178822
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effects of fenretinide metabolites N-[4-methoxyphenyl]retinamide (MPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (3-keto-HPR) on fenretinide molecular targets β-carotene oxygenase 1, stearoyl-CoA desaturase 1 and dihydroceramide Δ4-desaturase 1.
Poliakov E; Samuel W; Duncan T; Gutierrez DB; Mata NL; Redmond TM
PLoS One; 2017; 12(4):e0176487. PubMed ID: 28448568
[TBL] [Abstract][Full Text] [Related]
11. Distribution and metabolism of the retinoid, N-(4-methoxyphenyl)-all-trans-retinamide, the major metabolite of N-(4-hydroxyphenyl)-all-trans-retinamide, in female mice.
Hultin TA; Filla MS; McCormick DL
Drug Metab Dispos; 1990; 18(2):175-9. PubMed ID: 1971569
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of N-4-hydroxyphenyl-retinamide and the effect of its oral administration on plasma retinol concentrations in cancer patients.
Peng YM; Dalton WS; Alberts DS; Xu MJ; Lim H; Meyskens FL
Int J Cancer; 1989 Jan; 43(1):22-6. PubMed ID: 2521335
[TBL] [Abstract][Full Text] [Related]
13. Fenretinide breast cancer prevention trial: drug and retinol plasma levels in relation to age and disease outcome.
Formelli F; Camerini T; Cavadini E; Appierto V; Villani MG; Costa A; De Palo G; Di Mauro MG; Veronesi U
Cancer Epidemiol Biomarkers Prev; 2003 Jan; 12(1):34-41. PubMed ID: 12540501
[TBL] [Abstract][Full Text] [Related]
14. Effects of N-(4-hydroxyphenyl)retinamide on vitamin A metabolism in rats.
Adams WR; Smith JE; Green MH
Proc Soc Exp Biol Med; 1995 Feb; 208(2):178-85. PubMed ID: 7831350
[TBL] [Abstract][Full Text] [Related]
15. Relationship among pharmacokinetics and pharmacodynamics of fenretinide and plasma retinol reduction in neuroblastoma patients.
Formelli F; Cavadini E; Luksch R; Garaventa A; Appierto V; Persiani S
Cancer Chemother Pharmacol; 2010 Oct; 66(5):993-8. PubMed ID: 20532509
[TBL] [Abstract][Full Text] [Related]
16. The interaction of N-ethyl retinamide with plasma retinol-binding protein (RBP) and the crystal structure of the retinoid-RBP complex at 1.9-A resolution.
Zanotti G; Malpeli G; Berni R
J Biol Chem; 1993 Nov; 268(33):24873-9. PubMed ID: 8227049
[TBL] [Abstract][Full Text] [Related]
17. N-(4-hydroxyphenyl)retinamide: interactions with retinoid-binding proteins/receptors.
Sani BP; Shealy YF; Hill DL
Carcinogenesis; 1995 Oct; 16(10):2531-4. PubMed ID: 7586162
[TBL] [Abstract][Full Text] [Related]
18. Lack of correlation between plasmatic levels of retinol and RBP and thyroid hormones in breast cancer patients treated with the synthetic retinoid fenretinide.
Pizzichetta M; Formelli F; Bombardieri E; Bruni GF; Costa A
Int J Biol Markers; 1990; 5(4):208. PubMed ID: 2151235
[No Abstract] [Full Text] [Related]
19. Effects of N-(4-hydroxyphenyl)retinamide supplementation on vitamin A metabolism.
Lewis KC; Zech LA; Phang JM
Cancer Res; 1994 Aug; 54(15):4112-7. PubMed ID: 8033144
[TBL] [Abstract][Full Text] [Related]
20. Biotransformation and protein binding of N-(4-hydroxyphenyl)retinamide in murine mammary epithelial cells.
Bunk MJ; Kinahan JJ; Sarkar NH
Cancer Lett; 1985 Apr; 26(3):319-26. PubMed ID: 2986832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
